3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
13
fludarabine
11
Mycophenolic Acid
9
Busulfan
8
fludarabine phosphate
7
Tacrolimus
7
pirtobrutinib
6
Whole-Body Irradiation
6
Rituximab
6
Melphalan
6
Imatinib Mesylate
5
Bone Marrow Transplantation
5
ponatinib
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Azacitidine
4
venetoclax
3
nilotinib
3
lintuzumab
3
Stem Cell Transplantation
3
Sirolimus
3
Platelet Transfusion
3
Methotrexate
3
Cytarabine
3
Cyclosporine
3
Alemtuzumab
3
vosaroxin
2
ruxolitinib
2
ibrutinib
2
Thiotepa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
CLR1404
×
Other hematologic neoplasm
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled